Use is restricted to patients with locally-advanced or metastatic breast cancer who have progressive disease after at least two prior chemotherapeutic regimens for advanced disease which includes capecitabine if indicated. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.
Eribulin is licensed for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease.
Separately, NICE Technology Appraisal Guidance 250 does not recommend eribulin for people with locally advanced or metastatic breast cancer that has got worse after two or more courses of chemotherapy. Eribulin is currently listed on the NHS England Cancer Drugs Fund (ver 6.1) for use in patients with advanced breast cancer after failure of at least 2 prior chemotherapy regimens for advanced disease.